Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial

NCT02422368 is registered in ClinicalTrials.gov with Iran University of Medical Sciences as lead sponsor.

NCT NCT02422368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02422368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial
Lead sponsor
Iran University of Medical Sciences
Phase
Phase 2/3
Overall status
Withdrawn
Start date
September 1, 2022
Completion date
November 30, 2024
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease